Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTA-UBI(29-41)
- Development stage
- Unknown
- Lead developer
- Hospital Israelita Albert Einstein
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-DOTA-UBI(29-41) is an investigational radiolabeled peptide diagnostic agent designed for positron emission tomography (PET) imaging of bacterial infections. It consists of the synthetic cationic antimicrobial peptide fragment ubiquicidin 29-41 (UBI 29-41) conjugated to the chelator DOTA and labeled with the positron-emitting radioisotope gallium-68 (68Ga). The cationic peptide fragment specifically targets the anionic membranes of viable bacteria, allowing the tracer to accumulate at sites of active bacterial infection. This mechanism enables the differentiation of bacterial infections, such as chronic osteomyelitis and bone or soft-tissue infections, from sterile inflammation. The radiopharmaceutical is primarily developed within academic and hospital radiopharmacy settings, with clinical evaluation including pilot PET/CT studies in patients with chronic osteomyelitis.
- Other names
- [68Ga]Ga-DOTA-UBI(29-41)[68Ga]Ga-DOTA-Ubiquicidin29-4168Ga-DOTA-UBI 29-4168Ga-DOTA-Ubiquicidin 29-4168Ga-DOTA-Ubiquicidin(29-41)68Ga-UBI68Ga-UBI 29-4168Ga-UBI(29-41)
Beyond the preview
Go deeper on 68Ga-DOTA-UBI(29-41).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTA-UBI(29-41).